LAGE3

Summary

LAGE3 (L antigen family member 3, HGNC:26058) is a protein-coding gene on chromosome Xq28, encoding EKC/KEOPS complex subunit LAGE3 (Q14657). Component of the EKC/KEOPS complex that is required for the formation of a threonylcarbamoyl group on adenosine at position 37 (t(6)A37) in tRNAs that read codons beginning with adenine. It is a selective cancer dependency (DepMap: 11.3% of cell lines).

This gene belongs to the ESO/LAGE gene family, members of which are clustered together on chromosome Xq28, and have similar exon-intron structures. Unlike the other family members which are normally expressed only in testis and activated in a wide range of human tumors, this gene is ubiquitously expressed in somatic tissues. The latter, combined with the finding that it is highly conserved in mouse and rat, suggests that the encoded protein is functionally important. An intronless pseudogene with high sequence similarity to this gene is located on chromosome 9.

Source: NCBI Gene 8270 — RefSeq curated summary.

At a glance

• Gene–disease (curated): Galloway-Mowat syndrome 2, X-linked (Strong, GenCC) — +1 more curated relationship
• Clinical variants (ClinVar): 109 total — 3 pathogenic
• Phenotypes (HPO): 49
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 11.3% of screened cell lines
• MANE Select transcript: NM_006014

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26058
Approved symbol	LAGE3
Name	L antigen family member 3
Location	Xq28
Locus type	gene with protein product
Status	Approved
Aliases	ITBA2, CVG5, DXS9951E, DXS9879E, ESO3, Pcc1
Ensembl gene	ENSG00000196976
Ensembl biotype	protein_coding
OMIM	300060
Entrez	8270

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000357360

RefSeq mRNA: 1 — MANE Select: NM_006014 NM_006014

CCDS: CCDS14753

Canonical transcript exons

ENST00000357360 — 3 exons

Exon	Start	End
ENSE00001408883	154478283	154478411
ENSE00001431841	154478728	154479281
ENSE00001929073	154477775	154478058

Expression profiles

Bgee: expression breadth ubiquitous, 273 present calls, max score 98.23.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 30.4745 / max 179.3704, expressed in 1808 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
201029	11.0139	1736
201028	9.6523	1755
201025	4.6404	1453
201026	2.2392	1069
201032	1.8785	965
201031	0.4757	275
201027	0.3793	221
201030	0.1952	81

Top tissues by expression

292 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oocyte	CL:0000023	98.23	gold quality
secondary oocyte	CL:0000655	95.55	gold quality
Brodmann (1909) area 10	UBERON:0013541	94.69	gold quality
middle frontal gyrus	UBERON:0002702	93.97	gold quality
endometrium epithelium	UBERON:0004811	93.53	gold quality
frontal pole	UBERON:0002795	93.37	gold quality
anterior cingulate cortex	UBERON:0009835	92.96	gold quality
cingulate cortex	UBERON:0003027	92.93	gold quality
Brodmann (1909) area 9	UBERON:0013540	92.41	gold quality
nucleus accumbens	UBERON:0001882	91.94	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	91.92	gold quality
right frontal lobe	UBERON:0002810	91.66	gold quality
putamen	UBERON:0001874	91.60	gold quality
endothelial cell	CL:0000115	91.55	gold quality
amygdala	UBERON:0001876	91.51	gold quality
caudate nucleus	UBERON:0001873	91.35	gold quality
prefrontal cortex	UBERON:0000451	90.88	gold quality
neocortex	UBERON:0001950	90.75	gold quality
frontal cortex	UBERON:0001870	90.61	gold quality
cerebral cortex	UBERON:0000956	90.47	gold quality
telencephalon	UBERON:0001893	90.19	gold quality
pituitary gland	UBERON:0000007	90.14	gold quality
Ammon’s horn	UBERON:0001954	90.08	gold quality
forebrain	UBERON:0001890	89.95	gold quality
temporal lobe	UBERON:0001871	89.64	gold quality
paraflocculus	UBERON:0005351	89.63	gold quality
adenohypophysis	UBERON:0002196	89.61	gold quality
brain	UBERON:0000955	88.95	gold quality
central nervous system	UBERON:0001017	88.91	gold quality
left adrenal gland cortex	UBERON:0035825	88.74	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-CURD-112	yes	9.98
E-ANND-3	yes	8.78
E-CURD-10	no	52.21

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

15 targeting LAGE3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-802	99.61	67.70	1254
HSA-MIR-4328	99.57	71.06	4094
HSA-MIR-548B-3P	99.38	67.26	1000
HSA-MIR-20B-3P	99.29	67.05	784
HSA-MIR-488-5P	99.28	68.12	821
HSA-MIR-6840-3P	98.68	65.95	1923
HSA-MIR-4290	98.51	65.17	907
HSA-MIR-5008-5P	98.42	65.87	1019
HSA-MIR-4511	98.32	67.97	1500
HSA-MIR-562	97.66	65.63	698

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 11.3% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 6)

• Upregulation of LAGE3 correlates with prognosis and immune infiltrates in colorectal cancer: A bioinformatic analysis. (PMID:32438075)
• LAGE3 correlates with tumorigenic immune infiltrates in the clear cell renal cell carcinoma microenvironment. (PMID:32683301)
• lncRNA NEAT1 regulates the proliferation and migration of hepatocellular carcinoma cells by acting as a miR320a molecular sponge and targeting L antigen family member 3. (PMID:32945386)
• Identification and validation of L Antigen Family Member 3 as an immune-related biomarker associated with the progression of papillary thyroid cancer. (PMID:33310661)
• LAGE3 promoted cell proliferation, migration, and invasion and inhibited cell apoptosis of hepatocellular carcinoma by facilitating the JNK and ERK signaling pathway. (PMID:34837962)
• LAGE3 promotes cell metastasis and stemness in non-small cell lung cancer companied with AKT/PI3K signaling pathway activation. (PMID:37473499)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio		ENSDARG00000116344
mus_musculus	Lage3	ENSMUSG00000015289
drosophila_melanogaster	Tcs6	FBGN0260224

Paralogs (3): CTAG2 (ENSG00000126890), CTAG1B (ENSG00000184033), CTAG1A (ENSG00000268651)

Protein

Protein identifiers

EKC/KEOPS complex subunit LAGE3 — Q14657 (reviewed: Q14657)

Alternative names: L antigen family member 3, Protein ESO-3, Protein ITBA2

All UniProt accessions (1): Q14657

UniProt curated annotations — full annotation on UniProt →

Function. Component of the EKC/KEOPS complex that is required for the formation of a threonylcarbamoyl group on adenosine at position 37 (t(6)A37) in tRNAs that read codons beginning with adenine. The complex is probably involved in the transfer of the threonylcarbamoyl moiety of threonylcarbamoyl-AMP (TC-AMP) to the N6 group of A37. LAGE3 functions as a dimerization module for the complex.

Subunit / interactions. Component of the EKC/KEOPS complex composed of at least GON7, TP53RK, TPRKB, OSGEP and LAGE3; the whole complex dimerizes.

Subcellular location. Cytoplasm. Nucleus.

Tissue specificity. Ubiquitous.

Disease relevance. Galloway-Mowat syndrome 2, X-linked (GAMOS2) [MIM:301006] A form of Galloway-Mowat syndrome, a severe renal-neurological disease characterized by early-onset nephrotic syndrome associated with microcephaly, central nervous system abnormalities, developmental delays, and a propensity for seizures. Brain anomalies include gyration defects ranging from lissencephaly to pachygyria and polymicrogyria, and cerebellar hypoplasia. Most patients show facial dysmorphism characterized by a small, narrow forehead, large/floppy ears, deep-set eyes, hypertelorism and micrognathia. Additional variable features are visual impairment and arachnodactyly. Most patients die in early childhood. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the CTAG/PCC1 family.

RefSeq proteins (1): NP_006005* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR015419	CTAG/Pcc1	Family

Pfam: PF09341

UniProt features (11 total): strand 3, helix 2, sequence variant 2, chain 1, region of interest 1, compositionally biased region 1, turn 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
6GWJ	X-RAY DIFFRACTION	1.95
9FL9	ELECTRON MICROSCOPY	3.74

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q14657-F1	76.32	0.45

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-6782315	tRNA modification in the nucleus and cytosol
R-HSA-72306	tRNA processing
R-HSA-8953854	Metabolism of RNA

MSigDB gene sets: 231 (showing top): BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, KAAB_FAILED_HEART_ATRIUM_DN, PAL_PRMT5_TARGETS_UP, GOBP_TRNA_METABOLIC_PROCESS, RIZKI_TUMOR_INVASIVENESS_3D_DN, PATIL_LIVER_CANCER, GOBP_TRANSLATION, WATANABE_RECTAL_CANCER_RADIOTHERAPY_RESPONSIVE_UP, YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_13, GOBP_TRNA_THREONYLCARBAMOYLADENOSINE_METABOLIC_PROCESS, HAN_SATB1_TARGETS_DN, MARKEY_RB1_ACUTE_LOF_UP, MARTORIATI_MDM4_TARGETS_FETAL_LIVER_UP, DANG_BOUND_BY_MYC, CONCANNON_APOPTOSIS_BY_EPOXOMICIN_DN

GO Biological Process (2): tRNA processing (GO:0008033), tRNA threonylcarbamoyladenosine metabolic process (GO:0070525)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (5): EKC/KEOPS complex (GO:0000408), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), nuclear body (GO:0016604)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
tRNA processing	1
Metabolism of RNA	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
tRNA metabolic process	2
cellular anatomical structure	2
RNA processing	1
binding	1
transferase complex	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular anatomical structure	1
nucleoplasm	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

598 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LAGE3	OSGEP	Q9NPF4	998
LAGE3	TPRKB	Q9Y3C4	998
LAGE3	TP53RK	Q96S44	997
LAGE3	GON7	Q9BXV9	995
LAGE3	TMEM187	Q14656	943
LAGE3	OSGEPL1	Q9H4B0	852
LAGE3	YRDC	Q86U90	846
LAGE3	L1CAM	P32004	669
LAGE3	HCFC1	P51610	666
LAGE3	WDR73	Q6P4I2	628
LAGE3	FAM216A	Q8WUB2	497
LAGE3	TMEM101	Q96IK0	445
LAGE3	SLCO6A1	Q86UG4	432
LAGE3	CTAG2	O75638	430
LAGE3	RPP40	O75818	374

IntAct

124 interactions, top by confidence:

A	B	Type	Score
UBA5	GABARAPL2	psi-mi:“MI:0914”(association)	0.950
LAGE3	GON7	psi-mi:“MI:0915”(physical association)	0.880
GON7	LAGE3	psi-mi:“MI:0915”(physical association)	0.880
LAGE3	GON7	psi-mi:“MI:0407”(direct interaction)	0.880
GON7	LAGE3	psi-mi:“MI:0407”(direct interaction)	0.880
GON7	LAGE3	psi-mi:“MI:0914”(association)	0.880
LAGE3	OSGEP	psi-mi:“MI:0915”(physical association)	0.850
POP7	LAGE3	psi-mi:“MI:0915”(physical association)	0.740
KRT40	LAGE3	psi-mi:“MI:0915”(physical association)	0.720
LAGE3	KRT40	psi-mi:“MI:0915”(physical association)	0.720
IFT81	NDC80	psi-mi:“MI:0914”(association)	0.640
NAP1L5	IQGAP1	psi-mi:“MI:0914”(association)	0.640
VWCE	HSPA5	psi-mi:“MI:0914”(association)	0.640
PSMB9	LAGE3	psi-mi:“MI:0915”(physical association)	0.600
LAGE3	PDE9A	psi-mi:“MI:0915”(physical association)	0.560
PDE9A	LAGE3	psi-mi:“MI:0915”(physical association)	0.560
KRTAP10-8	LAGE3	psi-mi:“MI:0915”(physical association)	0.560
KRTAP6-3	LAGE3	psi-mi:“MI:0915”(physical association)	0.560
GOLGA6L9	LAGE3	psi-mi:“MI:0915”(physical association)	0.560
LAGE3	MID2	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (148): LAGE3 (Two-hybrid), KRT40 (Two-hybrid), LAGE3 (Affinity Capture-MS), LAGE3 (Affinity Capture-MS), LAGE3 (Co-fractionation), LAGE3 (Co-fractionation), LAGE3 (Co-fractionation), LAGE3 (Co-fractionation), LAGE3 (Co-fractionation), LAGE3 (Co-fractionation), LAGE3 (Co-fractionation), LAGE3 (Co-fractionation), LAGE3 (Co-fractionation), LAGE3 (Co-fractionation), LAGE3 (Affinity Capture-MS)

ESM2 similar proteins: A0JPP1, A1A4I4, A1A5B6, A4K436, A6QQ14, A6QQ47, C5IJB0, E1BSW7, O00459, O04173, O08908, O14908, O35465, P23726, P70268, Q12962, Q14318, Q14657, Q14919, Q16512, Q17QX2, Q1JQD7, Q32NY4, Q3B7U9, Q3MII6, Q3V1H9, Q496Y0, Q4R4E4, Q5C9Z4, Q5RE34, Q5XIU9, Q5ZIW1, Q63433, Q63788, Q6K461, Q6PZ03, Q6ZT62, Q7Z6J2, Q8CFK2, Q8HXH0

Diamond homologs: O75638, P78358, Q14657, Q9CR70, Q10220, Q6BNU4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

109 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	3
Likely pathogenic	0
Uncertain significance	56
Likely benign	18
Benign	10

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
444871	NM_006014.5(LAGE3):c.316G>T (p.Val106Phe)	Pathogenic
444872	NM_006014.5(LAGE3):c.410T>C (p.Phe137Ser)	Pathogenic
444873	NM_006014.5(LAGE3):c.188+1G>A	Pathogenic

SpliceAI

350 predictions. Top by Δscore:

Variant	Effect	Δscore
X:154478056:CGG:C	acceptor_gain	1.0000
X:154478057:GG:G	acceptor_gain	1.0000
X:154478059:C:CC	acceptor_gain	1.0000
X:154478054:AGCGG:A	acceptor_gain	0.9900
X:154478055:GCGG:G	acceptor_gain	0.9900
X:154478056:CGGC:C	acceptor_gain	0.9900
X:154478058:GC:G	acceptor_loss	0.9900
X:154478059:C:CA	acceptor_loss	0.9900
X:154478060:T:G	acceptor_loss	0.9900
X:154478065:G:C	acceptor_gain	0.9900
X:154478065:G:GC	acceptor_gain	0.9900
X:154478667:T:A	donor_gain	0.9800
X:154478753:C:CA	donor_gain	0.9800
X:154479036:AGGTC:A	donor_gain	0.9800
X:154479040:C:A	donor_gain	0.9700
X:154478726:A:AC	donor_gain	0.9600
X:154478727:C:CC	donor_gain	0.9600
X:154479134:T:A	donor_gain	0.9500
X:154478721:AGGAT:A	donor_loss	0.9400
X:154478722:GGATA:G	donor_loss	0.9400
X:154478723:GAT:G	donor_loss	0.9400
X:154478724:ATA:A	donor_loss	0.9400
X:154478725:T:TG	donor_loss	0.9400
X:154478057:G:T	acceptor_gain	0.9300
X:154478382:A:T	acceptor_gain	0.9300
X:154478727:CA:C	donor_gain	0.9300
X:154478727:CAAT:C	donor_gain	0.9300
X:154478748:TG:T	donor_gain	0.9300
X:154478727:CAA:C	donor_gain	0.9100
X:154479164:A:C	donor_gain	0.9000

AlphaMissense

910 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:154478367:G:T	A78D	0.977
X:154477965:A:C	F137L	0.974
X:154477965:A:T	F137L	0.974
X:154477967:A:G	F137L	0.974
X:154478393:G:C	F69L	0.966
X:154478393:G:T	F69L	0.966
X:154478395:A:G	F69L	0.966
X:154478054:A:G	W108R	0.960
X:154478054:A:T	W108R	0.960
X:154478394:A:G	F69S	0.956
X:154478377:C:G	A75P	0.955
X:154478315:C:A	K95N	0.939
X:154478315:C:G	K95N	0.939
X:154478017:A:T	V120D	0.938
X:154478394:A:C	F69C	0.933
X:154478400:A:T	V67E	0.932
X:154478052:C:A	W108C	0.929
X:154478052:C:G	W108C	0.929
X:154478053:C:G	W108S	0.927
X:154478007:A:C	F123L	0.925
X:154478007:A:T	F123L	0.925
X:154478009:A:G	F123L	0.925
X:154478048:C:G	A110P	0.920
X:154478370:A:C	I77S	0.909
X:154478283:A:T	V106D	0.902
X:154478395:A:T	F69I	0.899
X:154478411:G:C	F63L	0.898
X:154478411:G:T	F63L	0.898
X:154478729:A:G	F63L	0.898
X:154478008:A:G	F123S	0.895

dbSNP variants (sampled 300 via entrez): RS1000807733 (X:154478970 C>A), RS10011 (X:154477866 C>A,T), RS1001156590 (X:154478865 G>A,T), RS1002426504 (X:154477651 C>G), RS1003253315 (X:154481112 C>T), RS1005605707 (X:154479924 T>C), RS1007283352 (X:154478476 C>T), RS1012023429 (X:154478883 G>A), RS1013026504 (X:154480488 C>T), RS1013075516 (X:154480960 C>A,T), RS1013730007 (X:154477684 A>C,T), RS1013782347 (X:154477971 C>A,T), RS1018277707 (X:154479646 A>G), RS1018290595 (X:154479931 T>C), RS1020897902 (X:154478604 C>G,T)

Disease associations

OMIM: gene MIM:300060 | disease phenotypes: MIM:301006, MIM:300908, MIM:302060

GenCC curated gene-disease

Disease	Classification	Inheritance
Galloway-Mowat syndrome 2, X-linked	Strong	X-linked
Galloway-Mowat syndrome	Supportive	Autosomal recessive

Mondo (4): Galloway-Mowat syndrome 2, X-linked (MONDO:0033006), anemia, nonspherocytic hemolytic, due to G6PD deficiency (MONDO:0010480), Barth syndrome (MONDO:0010543), Galloway-Mowat syndrome (MONDO:0009627)

Orphanet (2): Barth syndrome (Orphanet:111), Class I glucose-6-phosphate dehydrogenase deficiency (Orphanet:466026)

HPO phenotypes

49 total (30 of 49 shown, HPO-id order):

HPO	Term
HP:0000093	Proteinuria
HP:0000097	Focal segmental glomerulosclerosis
HP:0000100	Nephrotic syndrome
HP:0000112	Nephropathy
HP:0000164	Abnormality of the dentition
HP:0000218	High palate
HP:0000252	Microcephaly
HP:0000316	Hypertelorism
HP:0000341	Narrow forehead
HP:0000347	Micrognathia
HP:0000400	Macrotia
HP:0000565	Esotropia
HP:0000601	Hypotelorism
HP:0000639	Nystagmus
HP:0000750	Delayed speech and language development
HP:0001166	Arachnodactyly
HP:0001181	Adducted thumb
HP:0001249	Intellectual disability
HP:0001250	Seizure
HP:0001252	Hypotonia
HP:0001257	Spasticity
HP:0001263	Global developmental delay
HP:0001272	Cerebellar atrophy
HP:0001276	Hypertonia
HP:0001302	Pachygyria
HP:0001310	Dysmetria
HP:0001419	X-linked recessive inheritance
HP:0001511	Intrauterine growth retardation
HP:0001622	Premature birth
HP:0002036	Hiatus hernia

GWAS associations

0 associations (top):

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D056889	Barth Syndrome	C14.240.400.172; C14.280.400.172; C16.131.077.121; C16.131.240.400.172; C16.320.322.068; C16.320.565.398.224; C18.452.584.563.224; C18.452.648.398.224
C567533	Anemia, Nonspherocytic Hemolytic, Due To G6pd Deficiency (supp.)
C537548	Galloway Mowat syndrome (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6066468 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases expression	2
Acetaminophen	increases expression, affects response to substance	2
Phenylmercuric Acetate	decreases expression, affects cotreatment	2
Valproic Acid	affects expression, decreases expression	2
2,4,6-tribromophenol	decreases expression	1
bisphenol A	decreases expression	1
methylselenic acid	decreases expression	1
decabromobiphenyl ether	decreases expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
mono-(2-ethylhexyl)phthalate	decreases expression	1
tetrabromobisphenol A	decreases expression	1
potassium chromate(VI)	decreases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, increases expression	1
di-n-butylphosphoric acid	affects expression	1
azoxystrobin	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment	1
pyrachlostrobin	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
jinfukang	increases expression	1
Sunitinib	decreases expression	1
Benzo(a)pyrene	affects methylation	1
Cisplatin	increases expression	1
Coumestrol	affects cotreatment, increases expression	1
Methotrexate	decreases expression	1
Smoke	decreases expression	1
Testosterone	increases expression	1
Dronabinol	decreases expression	1
Thiram	decreases expression	1
Tobacco Smoke Pollution	increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651676	Binding	Binding affinity to human LAGE3 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

9 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT07531251	PHASE4	NOT_YET_RECRUITING	Clinical Trial in Patients With Barth Syndrome- 4TAZPower
NCT03098797	PHASE2/PHASE3	COMPLETED	A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome
NCT01194141	Not specified	COMPLETED	Exercise Training in Barth Syndrome
NCT01461304	Not specified	NO_LONGER_AVAILABLE	Compassionate Use of Triheptanoin (C7) for Inherited Disorders of Energy Metabolism
NCT01625663	Not specified	COMPLETED	Heart and Muscle Metabolism in Barth Syndrome
NCT01629459	Not specified	COMPLETED	Resistance Exercise in Barth Syndrome
NCT03655223	Not specified	ENROLLING_BY_INVITATION	Early Check: Expanded Screening in Newborns
NCT04689360	Not specified	AVAILABLE	An Intermediate Size Expanded Access Protocol of Elamipretide
NCT05554835	Not specified	RECRUITING	Global Registry and Natural History Study for Mitochondrial Disorders